[go: up one dir, main page]

HU9701081D0 - Pharmaceutical composition of antitumoral activity - Google Patents

Pharmaceutical composition of antitumoral activity

Info

Publication number
HU9701081D0
HU9701081D0 HU9701081A HUP9701081A HU9701081D0 HU 9701081 D0 HU9701081 D0 HU 9701081D0 HU 9701081 A HU9701081 A HU 9701081A HU P9701081 A HUP9701081 A HU P9701081A HU 9701081 D0 HU9701081 D0 HU 9701081D0
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
antitumoral activity
pharmaceutically acceptable
addition salt
acid addition
Prior art date
Application number
HU9701081A
Other languages
English (en)
Original Assignee
Gene Research Lab Inc N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Research Lab Inc N filed Critical Gene Research Lab Inc N
Priority to HU9701081A priority Critical patent/HU9701081D0/hu
Publication of HU9701081D0 publication Critical patent/HU9701081D0/hu
Priority to TR1999/03214T priority patent/TR199903214T2/xx
Priority to CZ0462599A priority patent/CZ298468B6/cs
Priority to AT98925873T priority patent/ATE235918T1/de
Priority to IL13350898A priority patent/IL133508A/xx
Priority to NZ502039A priority patent/NZ502039A/xx
Priority to BR9810312-1A priority patent/BR9810312A/pt
Priority to DE69812949T priority patent/DE69812949T2/de
Priority to ES98925873T priority patent/ES2195344T3/es
Priority to UA2000010341A priority patent/UA64757C2/uk
Priority to PCT/IB1998/000961 priority patent/WO1998058676A1/en
Priority to AU77837/98A priority patent/AU735922B2/en
Priority to US09/446,064 priority patent/US6440998B1/en
Priority to DK98925873T priority patent/DK0993304T3/da
Priority to RU2000102359/14A priority patent/RU2214238C2/ru
Priority to CN98807103A priority patent/CN1127984C/zh
Priority to EP98925873A priority patent/EP0993304B1/en
Priority to CA002294913A priority patent/CA2294913C/en
Priority to SK1764-99A priority patent/SK282877B6/sk
Priority to JP50404999A priority patent/JP2002508762A/ja
Priority to PL337719A priority patent/PL191718B1/pl
Priority to HU9801404A priority patent/HUP9801404A3/hu
Priority to SI9830431T priority patent/SI0993304T1/xx
Priority to PT98925873T priority patent/PT993304E/pt
Priority to KR1019997012198A priority patent/KR20010020496A/ko
Priority to RU2003101319/15A priority patent/RU2254129C2/ru
Priority to NO19996349A priority patent/NO322206B1/no
Priority to HK01100914A priority patent/HK1029941A1/xx
Priority to US10/084,183 priority patent/US6656955B2/en
Priority to US10/084,095 priority patent/US6838469B2/en
Priority to US10/106,227 priority patent/US6720337B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9701081A 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity HU9701081D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
RU2003101319/15A RU2254129C2 (ru) 1997-06-23 1998-06-22 Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
RU2000102359/14A RU2214238C2 (ru) 1997-06-23 1998-06-22 Фармацевтическая композиция, обладающая противоопухолевым действием со сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
CN98807103A CN1127984C (zh) 1997-06-23 1998-06-22 含抗肿瘤药物和羟肟酸衍生物且具有抗肿瘤增强活性和/或副作用降低的药物组合物
AT98925873T ATE235918T1 (de) 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
IL13350898A IL133508A (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects containingan antitumor agent and an hydroximic acid derivative
NZ502039A NZ502039A (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
BR9810312-1A BR9810312A (pt) 1997-06-23 1998-06-22 Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
DE69812949T DE69812949T2 (de) 1997-06-23 1998-06-22 Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
ES98925873T ES2195344T3 (es) 1997-06-23 1998-06-22 Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
UA2000010341A UA64757C2 (uk) 1997-06-23 1998-06-22 Фармацевтична композиція з протипухлинною дією та/або зниженими побічними ефектами, спосіб підвищення ефективності та/або зниження побічних ефектів при лікуванні пухлинних захворювань, застосування похідної гідроксамової кислоти для підсилення протипухлинного ефекту та/або для зниження побічних ефектів відомого протипухлинного агента
PCT/IB1998/000961 WO1998058676A1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
AU77837/98A AU735922B2 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
US09/446,064 US6440998B1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
DK98925873T DK0993304T3 (da) 1997-06-23 1998-06-22 Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat
TR1999/03214T TR199903214T2 (xx) 1997-06-23 1998-06-22 Bir antit�m�r maddesi ve bir hidroksimik asit t�revini ihtiva eden, antit�m�r etkinli�i artt�r�lm�� ve yan etkileri d���r�lm�� farmas�tik bile�im.
EP98925873A EP0993304B1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
HU9801404A HUP9801404A3 (en) 1997-06-23 1998-06-22 Pharmaceutical composition of antitumoral activity
PT98925873T PT993304E (pt) 1997-06-23 1998-06-22 Composicao farmaceutica que apresenta actividade antitumoral intensificada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do acido hidroxamico
SK1764-99A SK282877B6 (sk) 1997-06-23 1998-06-22 Farmaceutický prostriedok so zvýšenou protinádorovou aktivitou a/alebo redukovanými nežiaducimi účinkami, použitie aktívnej substancie s protinádorovou aktivitou a použitie derivátu kyseliny hydroxímovej
JP50404999A JP2002508762A (ja) 1997-06-23 1998-06-22 抗腫瘍剤並びにヒドロキシム酸誘導体を含有し、増強された抗腫瘍活性および／または軽減された副作用を有する薬剤組成物
PL337719A PL191718B1 (pl) 1997-06-23 1998-06-22 Kompozycja farmaceutyczna o aktywności przeciwrakowej oraz zastosowanie amidoksymu O-(3-piperydyno-2-hydroksylo-1-propylo)nikotynowego
CZ0462599A CZ298468B6 (cs) 1997-06-23 1998-06-22 Farmaceutické prostredky se zesílenou protinádorovou aktivitou a/nebo sníženými nežádoucími úcinky obsahující protinádorové cinidlo a derivát kyseliny hydroximové
SI9830431T SI0993304T1 (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
CA002294913A CA2294913C (en) 1997-06-23 1998-06-22 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
KR1019997012198A KR20010020496A (ko) 1997-06-23 1998-06-22 항종양 활성의 증가 및/또는 부작용의 감소가 있는,항종양제 및 히드록심산 유도체를 함유하는 약제학적 조성물
NO19996349A NO322206B1 (no) 1997-06-23 1999-12-20 Farmasoytisk sammensetning som har antitumoraktivitet med reduserte bivirkninger, inneholdende et antitumormiddel og O-(3-piperidino-2-hydroksy-1-propyl) nikotin amidoksim og anvendelse av amidoksimet til fremstilling av en antitumor farmasoytisk sammensetning som reduserer bivirkningene.
HK01100914A HK1029941A1 (en) 1997-06-23 2001-02-09 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
US10/084,183 US6656955B2 (en) 1997-06-23 2002-02-28 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
US10/084,095 US6838469B2 (en) 1997-06-23 2002-02-28 Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity
US10/106,227 US6720337B2 (en) 1997-06-23 2002-03-27 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity

Publications (1)

Publication Number Publication Date
HU9701081D0 true HU9701081D0 (en) 1997-08-28

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity

Country Status (25)

Country Link
US (4) US6440998B1 (hu)
EP (1) EP0993304B1 (hu)
JP (1) JP2002508762A (hu)
KR (1) KR20010020496A (hu)
CN (1) CN1127984C (hu)
AT (1) ATE235918T1 (hu)
AU (1) AU735922B2 (hu)
BR (1) BR9810312A (hu)
CA (1) CA2294913C (hu)
CZ (1) CZ298468B6 (hu)
DE (1) DE69812949T2 (hu)
DK (1) DK0993304T3 (hu)
ES (1) ES2195344T3 (hu)
HK (1) HK1029941A1 (hu)
HU (1) HU9701081D0 (hu)
IL (1) IL133508A (hu)
NO (1) NO322206B1 (hu)
NZ (1) NZ502039A (hu)
PL (1) PL191718B1 (hu)
PT (1) PT993304E (hu)
RU (2) RU2254129C2 (hu)
SK (1) SK282877B6 (hu)
TR (1) TR199903214T2 (hu)
UA (1) UA64757C2 (hu)
WO (1) WO1998058676A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP2368553B1 (en) * 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008233129B2 (en) * 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
CA2704128A1 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN104447746A (zh) * 2013-09-18 2015-03-25 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
RU2139052C1 (ru) * 1993-03-31 1999-10-10 Мерк Энд Ко., Инк. Комбинация ингибитора вич-протеазы с другими антивирусными соединениями, фармацевтическая композиция на их основе и способ получения фармацевтической композиции
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
BR9810312A (pt) 2000-09-19
CN1127984C (zh) 2003-11-19
PT993304E (pt) 2003-08-29
DE69812949T2 (de) 2004-02-05
NZ502039A (en) 2002-03-28
CN1263471A (zh) 2000-08-16
TR199903214T2 (xx) 2000-12-21
WO1998058676A1 (en) 1998-12-30
CZ462599A3 (cs) 2000-05-17
NO996349L (no) 2000-02-23
NO322206B1 (no) 2006-08-28
US6838469B2 (en) 2005-01-04
US20030069270A1 (en) 2003-04-10
US20020147213A1 (en) 2002-10-10
AU7783798A (en) 1999-01-04
IL133508A0 (en) 2001-04-30
PL337719A1 (en) 2000-08-28
SK176499A3 (en) 2000-09-12
JP2002508762A (ja) 2002-03-19
DE69812949D1 (de) 2003-05-08
ATE235918T1 (de) 2003-04-15
EP0993304A1 (en) 2000-04-19
AU735922B2 (en) 2001-07-19
SK282877B6 (sk) 2003-01-09
US6440998B1 (en) 2002-08-27
UA64757C2 (uk) 2004-03-15
CZ298468B6 (cs) 2007-10-10
IL133508A (en) 2005-11-20
DK0993304T3 (da) 2003-07-28
KR20010020496A (ko) 2001-03-15
EP0993304B1 (en) 2003-04-02
RU2254129C2 (ru) 2005-06-20
US6656955B2 (en) 2003-12-02
PL191718B1 (pl) 2006-06-30
CA2294913C (en) 2008-12-16
ES2195344T3 (es) 2003-12-01
NO996349D0 (no) 1999-12-20
CA2294913A1 (en) 1998-12-30
HK1029941A1 (en) 2001-04-20
US6720337B2 (en) 2004-04-13
US20030050345A1 (en) 2003-03-13
RU2214238C2 (ru) 2003-10-20

Similar Documents

Publication Publication Date Title
HU9701081D0 (en) Pharmaceutical composition of antitumoral activity
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
BG106030A (en) Pharmaceutical composition
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MA26459A1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
MY127935A (en) Water-soluble pharmaceutical composition in an ionic complex and the use thereof
CA2133175A1 (en) Rapamycin formulations for oral administration
WO2001041737A3 (en) Solid oral dosage form
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
CA2270177A1 (en) Transdermal administration of ment
EP1230925B8 (en) Use of a trifluridine derivative alone or combined with a thymidine phosphorylase inhibitor for the treatment of hiv
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient
CA2347750A1 (en) Pharmaceutical composition containing decursin
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
EP1090639A3 (en) Pharmaceutical composition containing a progestational corticoid and a selective estrogen receptor modulator
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
AP2001002369A0 (en) Pharmaceutical complex.
ZA981430B (en) Anticancer composition
WO1998014454A3 (en) (o-ACYL-p-N-ACYLAMINO-PHENYL)-O-PHOSPHOETHANOLAMINES
WO1999043285A3 (en) Sulphonamide derivatives